Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | BCL2L11 | O43521 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7170053 | 0.79 | OPRM1 (0.47) | KDM1APTGDRPTGDR2 | |
| SCHEMBL367096 | 0.78 | AKR1C1 (0.47) | KDM1ASIGMAR1 | |
| SCHEMBL7967461 | 0.77 | POLA1 (0.52) | KDM1ASIGMAR1 | |
| SCHEMBL5396757 | 0.77 | POLA1 (0.52) | KDM1ASIGMAR1 | |
| SCHEMBL6810390 | 0.76 | AKR1C1 (0.39) | KDM1AKDM4C | |
| SCHEMBL6580380 | 0.76 | POLB (0.43) | SIGMAR1 | |
| SCHEMBL6605548 | 0.75 | MAP3K14 (0.49) | BACE1 | |
| SCHEMBL5399703 | 0.75 | MAP3K14 (0.49) | BACE1 | |
| SCHEMBL6605552 | 0.75 | MAP3K14 (0.49) | BACE1 | |
| SCHEMBL21333712 | 0.73 | KDM1A (0.47) | KDM1AKDM4CSRD5A1SRD5A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1205187-C | New amidino derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 2005-06-08 | — | — | CN | disclosed |
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| CN-1266427-A | Amidino derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 2000-09-13 | — | — | CN | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | KDM1A 3307/4885KDM4C 4746/4885SRD5A1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.